KalVista Pharmaceuticals (NASDAQ:KALV) Insider Nicole Sweeny Sells 1,489 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 1,489 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total value of $39,875.42. Following the sale, the insider owned 59,291 shares in the company, valued at approximately $1,587,812.98. This represents a 2.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nicole Sweeny also recently made the following trade(s):

• On Friday, May 22nd, Nicole Sweeny sold 1,861 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $26.78, for a total value of $49,837.58.
• On Friday, April 17th, Nicole Sweeny sold 1,862 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $20.22, for a total value of $37,649.64.

KalVista Pharmaceuticals Stock Down 0.1%

KALV opened at $26.79 on Thursday. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.83 and a 1-year high of $26.85. The stock’s fifty day simple moving average is $21.94 and its 200 day simple moving average is $17.65. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. The stock has a market cap of $1.43 billion, a PE ratio of -7.74 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $40.86 million during the quarter, compared to analyst estimates of $39.03 million. As a group, research analysts expect that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at $24,360,000. Jefferies Financial Group Inc. acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at $3,494,000. Blue Owl Capital Holdings LP acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at $1,522,000. Hennion & Walsh Asset Management Inc. grew its holdings in KalVista Pharmaceuticals by 93.6% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 341,819 shares of the specialty pharmaceutical company’s stock valued at $5,520,000 after buying an additional 165,236 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ grew its holdings in KalVista Pharmaceuticals by 391.9% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 200,991 shares of the specialty pharmaceutical company’s stock valued at $2,449,000 after buying an additional 160,128 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on KALV shares. Wall Street Zen cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. HC Wainwright cut KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $37.00 to $27.00 in a research note on Friday, May 1st. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 21st. Citizens Jmp cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Finally, JonesTrading cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 30th. Three equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $30.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.